Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan

The HAQ-DI is a patient-reported assessment of physical function that includes 20 items in eight categories representing a comprehensive set of functional activities, including dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst), with a higher score representing a high-dependency disability.

Time frame: Baseline and Week 24

Population: Participants who were still receiving adalimumab at week 24 and with available HAQ-DI data at baseline and week 24.

The EQ-5D-5L descriptive system comprises 5 dimensions of health-related quality of life states (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which can take one of three responses. The responses record three levels of severity ('no problems', 'some problems', and 'extreme problems') within a particular EQ-5D-3L dimension. The EQ-5D-3L results were converted into a weighted health state index with scores ranging from approximately 0 (death) to 1 (full health). A positive change from baseline indicates improvement.

Time frame: Baseline, week 12, and week 24

Population: Participants still receiving adalimumab and with available data at each time point.

The HAQ-DI is a patient-reported assessment of physical function that includes 20 items in eight categories representing a comprehensive set of functional activities, including dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst), with a higher score representing a high-dependency disability.

Time frame: Week 0 and Week 12

Population: Participants who were still receiving adalimumab at week 24 and with available HAQ-DI data at baseline and week 24.

The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The summary physical health score included the following subscales: physical functioning, role-physical, bodily pain, and general health. The summary mental health score included the following subscales: vitality, social functioning, role-emotional, and mental health. Each score ranges from 0 to 100 where higher scores indicate a better quality of life. A positive change from Baseline score indicates an improvement.

Time frame: Baseline, week 12, and week 24

Population: Participants still receiving adalimumab and with available data at each time point.

The Work Productivity and Activity Impairment (WPAI) questionnaire for general health is a validated tool in RA consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.

Time frame: Baseline, week 12, and week 24

Population: Participants still receiving adalimumab and with available data at each time point. Overall work impairment was only assessed in participants who were employed.

The healthcare resource utilization (HCRU) questionnaire collected data on the healthcare resources used over the course of the study.

Time frame: 24 weeks

Population: All enrolled participants

The healthcare resource utilization (HCRU) questionnaire collected data on the healthcare resources used over the course of the study.

Time frame: 24 weeks

Population: All enrolled participants

The healthcare resource utilization (HCRU) questionnaire collected data on the healthcare resources used over the course of the study.

Time frame: 24 weeks

Population: All enrolled participants

The healthcare resource utilization (HCRU) questionnaire collected data on the healthcare resources used over the course of the study.

Time frame: 24 weeks

Population: All enrolled participants

The HAQ-DI is a patient-reported assessment of physical function that includes 20 items in eight categories representing a comprehensive set of functional activities, including dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst), with a higher score representing a high-dependency disability. A clinically meaningful improvement was defined as an improvement of -0.22 points or greater in the HAQ-DI score.

Time frame: Baseline, week 12 and week 24

Population: Participants still receiving adalimumab and with available data at each time point.